Related Experiment Video
Updated: Aug 14, 2026
Adenovirus-mediated Genetic Removal of Signaling Molecules in Cultured Primary Mouse Embryonic Fibroblasts
Published on: September 9, 2010
Transgene expression in the rhesus cervix mediated by an adenovirus expressing beta-galactosidase
M F Mitchell1, K Hamada, K J Sastry
1Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.
Objectives:
More than 90% of cervical cancers are positive for human papillomavirus, which functionally represses p53 and pRb. The remainder have been found to contain p53 mutations. Gene therapy involves insertion of a functioning gene into a patient to correct a genetic abnormality.
Study Design:
The ability of a beta-galactosidase adenovirus to mediate transgene expression in the rhesus cervix was evaluated. Three different doses and two different entry techniques of virus were investigated.
Results:
The ideal dose determined by X-galactosidase staining was 2 x 10(10) plaque-forming units, and the injection method yielded better staining than did abrasion with topical application. Increased adenoviral-specific immunoglobulin G antibody response in the injected monkeys confirmed the results.
Conclusion:
High transduction efficiency by use of adenoviral vectors can be achieved in the cervix. Reversing the effects of human papillomavirus and p53 mutations with gene therapy may become a novel therapy for invasive and preinvasive cervical cancer.
Insights
Gene therapy using adenoviral vectors shows promise for cervical cancer. This study optimized delivery methods, achieving high gene expression in the cervix for potential novel treatments.
Area of Science:
- Oncology
- Gene Therapy
- Virology
Background:
- Cervical cancers are predominantly linked to human papillomavirus (HPV), which inactivates tumor suppressors p53 and pRb.
- A subset of cervical cancers exhibit p53 mutations, necessitating alternative therapeutic strategies.
- Gene therapy offers a potential approach to correct genetic abnormalities driving cancer development.
Purpose of the Study:
- To evaluate the efficacy of a beta-galactosidase adenovirus for mediating transgene expression in the rhesus cervix.
- To determine optimal viral dosage and delivery methods for cervical gene therapy.
Main Methods:
- Adenoviral vector administration with varying doses (2 x 10(10) plaque-forming units) and delivery techniques (injection vs. abrasion).
- Assessment of transgene expression via X-galactosidase staining.
- Measurement of adenoviral-specific immunoglobulin G antibody response.
Main Results:
- The optimal viral dose was identified as 2 x 10(10) plaque-forming units.
- Cervical injection proved more effective for transgene delivery than topical abrasion.
- Increased adenoviral-specific antibody responses confirmed successful transduction in vivo.
Conclusions:
- Adenoviral vectors can achieve high transduction efficiency in the cervix.
- Gene therapy holds potential as a novel treatment for preinvasive and invasive cervical cancers by addressing HPV effects and p53 mutations.
